CanadaTuberculosis profile
Population  2016 36 million
Estimates of TB burden*, 2016 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.099 (0.098–0.1) 0.27 (0.27–0.27)
Mortality (HIV+TB only) 0.023 (0.015–0.033) 0.06 (0.04–0.09)
Incidence  (includes HIV+TB) 1.9 (1.6–2.2) 5.2 (4.4–6)
Incidence (HIV+TB only) 0.15 (0.12–0.18) 0.41 (0.34–0.49)
Incidence (MDR/RR-TB)** 0.019 (<0.01–0.031) 0.05 (0.02–0.09)
Estimated TB incidence by age and sex (thousands)*, 2016
  0-14 years > 14 years Total
Females 0.067 (0.057–0.077) 0.81 (0.69–0.94) 0.88 (0.75–1)
Males 0.076 (0.064–0.087) 0.92 (0.79–1.1) 1 (0.85–1.1)
Total 0.14 (0.12–0.16) 1.7 (1.5–2) 1.9 (1.6–2.2)
TB case notifications, 2016  
Total cases notified 1 738
Total new and relapse 1 738
          - % tested with rapid diagnostics at time of diagnosis  
          - % with known HIV status 44%
          - % pulmonary 72%
          - % bacteriologically confirmed among pulmonary 91%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2016 92% (80–110)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2016 0.07 (0.06–0.08)
TB/HIV care in new and relapse TB patients, 2016 Number (%)
Patients with known HIV-status who are HIV-positive 97 13%
          - on antiretroviral therapy    
Drug-resistant TB care, 2016 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  15
(6–23)
Estimated % of TB cases with MDR/RR-TB 0.82% (0.33–1.7) 6.3% (1.7–15)  
% notified tested for rifampicin resistance 79% 80% 1 403
MDR/RR-TB cases tested for resistance to second-line drugs   16
Laboratory-confirmed cases MDR/RR-TB: 16, XDR-TB: 0
Patients started on treatment **** MDR/RR-TB: 16, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2015 84% 1 642
Previously treated cases, excluding relapse, registered in 2015    
HIV-positive TB cases registered in 2015 84% 67
MDR/RR-TB cases started on second-line treatment in 2014 87% 23
XDR-TB cases started on second-line treatment in 2014   0
TB preventive treatment, 2016  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2017  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2016
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2018-01-18 Data: www.who.int/tb/data